Takeda’s Alunbrig (ingredient: brigatinib), a treatment for anaplastic lymphoma kinase(ALK)-positive non-small cell lung cancer (NSCLC), is likely to get health insurance benefits in the first-line therapy within the first half of this year and compete against Alecensa, sources said.On Jan. 27, the
Shareholders of Medytox have taken collective action to demand the company’s explanation regarding the revocation of the permit for Innotox, a botulinum toxin (BTX) product.They also warned that they could file a lawsuit to demand the dismissal of Medytox CEO Jung Hyun-ho.Law firm Oh Kims Law &Co. s
KB Pharm said it would cooperate with two Swiss partners to enter the U.S. and European antibiotic market.The drugmaker, an affiliate of Chong Kun Dang, has signed a CMO (contract manufacturing organization) deal with Basilea Pharmaceutica International, a multinational antibiotics developer, to sup
Hanmi Pharmaceutical said Thursday that its annual sales increased in 2020, but its operating and net profit declined due to the export drop caused by the Covid-19 and revoked technology transfer deal with Sanofi.The company’s operating profit plunged 53.1 percent to 48.7 billion won, from 103.9 bil
Korean pharmaceutical companies pulled the plug on more than 4,000 drugs last year to increase their profitability.The number of drugs withdrawn from the market has increased significantly since the government implemented an item renewal system in 2018, allowing pharmaceutical companies to throw out
Eisai’s Lenvima is threatening Bayer’s Nexavar, the No. 1 drug in the liver cancer treatment market. Lenvima’s outpatient prescriptions jumped 132 percent in 2020 compared to a year earlier, while those of Nexavar dropped 31 percent.U-BIST data, analyzed by Korea Biomedical Review, has shown that ou
Biopharmaceutical companies planning to make initial public offerings through the “special technology listing system” are on the strain after the Korea Exchange (KRX) drastically strengthened standards for such qualifications this year.Some are pushing ahead with their initial plans, but others have
The share prices of Hanall Biopharma, a subsidiary of Daewoong Pharmaceutical, plunged Tuesday after its global partner, Immunovant, suspended the phase 2 clinical trials of its eye disease drug candidate, IMVT-1401.The U.S. company said on Tuesday (local time) that it had observed physiological sig
Eli Lilly Korea's Taltz, an interleukin (IL)-17A inhibitor that recently began to receive insurance benefits, will become a new alternative for treating local ankylosing spondylitis patients, according to a researcher who conducted clinical trials with the drug."Only one in three local patients with
Korean pharmaceutical and biotech companies are rushing to develop a Covid-19 treatment using natural ingredients.They are aggressively conducting trials, particularly in India, because the country has many Covid-19 cases and high unmet clinical needs.Last year, India eased drug regulations on the n
Employees transferred from MSD Korea to its spinoff company Organon Korea said they would form a trade union to solidify job security.Han Il-ho, the leader in preparing a labor union at Organon Korea, said he submitted the application for establishing a union to the Seoul Regional Employment and Lab
Korean biopharmaceutical companies signed technology transfer deals worth more than 10 trillion won ($8.96 billion) last year. However, they saw nearly 80 percent of such deals go up in smoke due to the cancellation of contracts by multinational giants, industry sources said Tuesday.Global pharmaceu
inno.N said it would begin licensing procedure to launch its gastroesophageal reflux disease (GERD) therapy, K-CAB tablets, in the Chinese market. K-CAB tablet is Korea’s 30th new drug licensed out to Shandong Luoxin Pharmaceutical Group at $95 million. The Chinese partner seeks to launch the new tr
Hanmi Pharmaceutical said Monday that it has launched Amosartan XQ, the world's first four-ingredient combination therapy."The drug, which treats hypertension and hyperlipidemia, combines two hypertension treatments (amlodipine and losartan) and two dyslipidemia treatments (rosuvastatin and ezetimib
GSK’s systemic lupus erythematosus (SLE) treatment Benlysta (ingredient: belimumab) has obtained health insurance benefits on Monday. Among patients aged 18 or more with active SLE who are autoantibody-positive and who have been receiving the standard therapy for more than three months, those who me
SK Biopharmaceuticals said the European Medicines Agency (EMA)'s Committee for Medicinal Products for Human Use (CHMP) recommended authorizing the Korean company’s antiepileptic drug's regional sales, Cenobamate, on Friday.Given the European Commission’s final authorization comes within 67 days of r
Leclaza (ingredient: lazertinib), Korea’s 31st novel drug that treats lung cancer, is likely to become a globally competitive new treatment, experts said.Its effectiveness and safety proven in clinical trials are likely to show in real clinical settings, they added.Yuhan Corp.’s treatment for non-sm
Korea’s sleeping pill market, as represented by zolpidem, showed a stable growth amid the Covid-19 pandemic last year.The top 10 zolpidem drugs' prescription amounted to 19.8 billion won ($17.7 million) last year, up 6.39 percent from 2019.Zolpidem tartrate drugs are used the most among sleeping pil
Daewoong Pharmaceutical said Friday that it would request the U.S. Food and Drug Administration to investigate Medytox's liquid type botulinum toxin (BTX) product, Innotox. Daewoong's move comes after the Ministry of Food and Drug Safety revoked the license of Innotox from Tuesday for allegedly usin
The executive board of diagnostic kit maker, Solgent, has reelected Seok Do-soo as CEO, taking management control from its largest shareholder Eone Diagnomics (EDGC). The board, while reinstating Seok who represents small individual shareholders, dismissed current Co-CEO You Jae-hyung and Lee Myung-